Clinical Trial Finder

Inclusion Criteria:

• - Age >= 18 years.

• - Disease characteristics: - Progressive or recurrent World Health Organization (WHO) Grade IV IDH wildtype glioblastoma (including molecular glioblastoma and gliosarcoma) - Previously treated with maximum feasible resection or biopsy, radiation, and temozolomide.

• - Have an enhancing mass on magnetic resonance imaging (MRI) amenable to resection or biopsy of the tumor (as determined by the neurosurgeon pre-operatively) and histological diagnosis of glioblastoma from a prior biopsy or surgery.

• - Willing to undergo clinically indicated resection or biopsy of their glioblastoma at Mayo Clinic in Rochester, Minnesota (MN).

• - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 and Karnofsky Performance Scale (KPS) >= 70 NOTE: PS must be assessed (again) within 7 days prior to first dose of study drug.

• - Hemoglobin >= 9.0 g/dL (obtained =< 15 days prior to registration) (without transfusion or erythropoietin [EPO] dependency =< 7 days prior to assessment) - Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 15 days prior to registration) - Platelet count >= 100,000/mm^3 (obtained =< 15 days prior to registration) - Creatinine =< 1.5 x upper limits of normal (ULN) OR measured or calculated creatinine clearance (per institutional standard) must be >= 45 ml/min (obtained =< 15 days prior to registration) - Total bilirubin =<1.5 x ULN OR direct bilirubin =< ULN for patients with total bilirubin levels >1.5 x ULN (obtained =< 15 days prior to registration) - Aspartate transaminase (AST) AND alanine transaminase (ALT) =< 2.5 x ULN (obtained =< 15 days prior to registration) - Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN OR if patient is receiving anticoagulant therapy then INR or aPTT is within target range of therapy (obtained =< 15 days prior to registration) - Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only (POCBP) Note: If testing done for eligibility is > 72 hours prior to first dose, then pregnancy testing must be repeated, and result must be negative for patient to receive treatment.

• - POCBP or able to father a child must be willing to use adequate contraception starting with first dose through 180 days after last dose.

• - Provide written informed consent.

• - Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study).

• - Willing to provide tissue and blood samples for correlative research purposes.

Exclusion Criteria:

• - Any of the following because this study involves an investigational agent for which genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown: - Pregnant persons.

• - Nursing persons.

• - Persons of childbearing potential or able to father a child who are unwilling to employ adequate contraception.

• - Signs or symptoms of life-threatening raised intracranial pressure: as determined by the treating neurosurgeon, including severe headache, nausea, decreasing level of consciousness, precluding 4-7-day delay in scheduling neurosurgery (i.e., immediate surgery is indicated, and patient cannot wait).

• - Prior treatment.

• - Received bevacizumab (AVASTIN) =< 4 months prior to registration.

• - Note: Bevacizumab is allowed for symptom control during the adjuvant phase of the study.

• - Received a live vaccine =< 30 days prior to registration.

• - Requirement for dexamethasone dose of > 2mg/day =< 2 days prior to registration.

• - Failure to recover from any adverse events related to any of the following therapies received prior to registration: - Major surgery =< 28 days prior to registration.

• - Radiation therapy =< 14 days prior to registration.

• - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

• - Known history of human immunodeficiency virus (HIV) infection.

• - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations (e.g., drug addiction) that would limit compliance with study requirements.

• - Receiving any other investigational agent.

• - Other active malignancy requiring systemic treatment =< 1 year prior to registration.

• - History of myocardial infarction =< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.

• - Active autoimmune disease that has required systemic treatment (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) =< 2 years prior to registration NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

• - Concurrent known active Hepatitis B (i.e., known positive hepatitis B virus [HBV] surface antigen [HBsAg] reactive) AND known active Hepatitis C (i.e., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] detected by polymerase chain reaction [PCR]) - Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.

• - NOTE: Patients with known Hepatitis B OR Hepatitis C may be enrolled if they meet the following criteria: - Hepatitis B: Patients who are HBsAG positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.

Patients should remain on anti-viral therapy throughout the treatment phase of the trial and should follow local guidelines for HBV anti-viral therapy after completing study treatment.

• - Hepatitis C: Patients with history of Hepatitis C infection are eligible if HCV viral load is undetectable at screening.

Patients must have completed curative anti-viral therapy at least 4 weeks prior to registration.

• - Known history of active TB (Bacillus Tuberculosis) - History of (non-infectious) pneumonitis or interstitial lung disease that required steroids, or current pneumonitis or interstitial lung disease.

• - Hypersensitivity to pembrolizumab or any of its excipients.

• - Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

- History of allogenic tissue/solid organ transplant

PRIMARY OBJECTIVE:

• I. To determine the efficacy of pembrolizumab + efineptakin alfa (NT-I7) in combination with surgery in patients with recurrent glioblastoma multiforme (GBM) using the rate of overall survival at 9 months.

SECONDARY OBJECTIVES:

• I. To assess progression-free survival in recurrent GBM patients treated with pembrolizumab + NT-I7 in combination with surgery.

• II. To determine the objective response rate in recurrent GBM patients treated with pembrolizumab + NT-I7 in combination with surgery.

• III. To assess changes in absolute lymphocyte counts (ALC) over time in recurrent GBM patients treated with pembrolizumab + NT-I7 in combination with surgery.

TERTIARY OBJECTIVES:

• I. To assess the adverse event (AE) and toxicity profile of pembrolizumab + NT-I7 in combination with surgery in patients with recurrent GBM.

• II. To assess the anti-glioma immune response in patients with recurrent GBM, before and after pembrolizumab and NT-I7 treatment, including assessment of cytokine profiling, immune cell phenotyping, function, and activation in the pre/post-treatment blood and tumor tissue when available.

• III. To test tumor mutation burden on tumor/immune cells by validated comprehensive genomic profiling.

• IV. To evaluate the changes for tumor microenvironment (TME) post pembrolizumab and NT-I7 and their correlations with treatment response and survival.

• V. To evaluate tumor infiltrating lymphocytes (CD4, CD8, Treg, etc) in the tumor tissue pre- and post-treatment (when available).

• VI. To assess changes in repertoire breadth and clonality by T-cell receptor (TCR) sequencing.

• VII. To explore potential tissue and blood biomarkers that may predict response.

OUTLINE: BEFORE SURGERY: Patients receive pembrolizumab intravenously (IV) over 30 minutes and efineptakin alfa intramuscularly (IM) on day 1. Patients then undergo surgery 1 week later. AFTER SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1 of each cycle. Cycles repeat every 42 days for 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and every 2-3 months until disease progression (if applicable), and then every 6 months for up to 5 years from study registration.

Arms

Experimental: Treatment (efineptakin alfa, pembrolizumab)

BEFORE SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1. Patients then undergo surgery 1 week later. AFTER SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1 of each cycle. Cycles repeat every 42 days for 2 years in the absence of disease progression or unacceptable toxicity.

Interventions

Procedure: - Biospecimen Collection

Correlative studies

Biological: - Efineptakin alfa

Given IM

Biological: - Pembrolizumab

Given IV